Craft

AMAG Pharmaceuticals

Revenue

$327.8 M

FY, 2019

AMAG Pharmaceuticals Summary

Company Summary

Overview
AMAG Pharmaceuticals is a pharmaceutical company that develops and delivers medicines across a range of therapeutic areas. Its core products include Makena, a hydroxyprogesterone caproate injection that helps reduce the risk of preterm birth in women with a singleton pregnancy, and Feraheme, a ferumoxytol injection for the treatment of iron deficiency anemia (IDA) in adult patients.
Type
Subsidiary
Status
Active
Founded
1981
HQ
Waltham, MA, US | view all locations
Website
https://www.amagpharma.com
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Michael Porter, President

    • Ozgur Kilic, CFO

      Operating MetricsView all

      Products

      4

      FY, 2019

      LocationsView all

      1 location detected

      • Waltham, MA HQ

        United States

        1100 Winter St

      AMAG Pharmaceuticals Financials

      Summary Financials

      Revenue (Q3, 2020)
      $93.1M
      Gross profit (Q3, 2020)
      $79.8M
      Net income (Q3, 2020)
      $9.7M
      Cash (Q3, 2020)
      $98.0M
      EBIT (Q3, 2020)
      $1.6M

      Footer menu